# US 2016/0243055 A1 · Cannabidiol for treatment of severe and refractory graft-versus-host disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0243055 A1
- Document ID: US20160243055A1
- Status: Published application
- Kind: A1
- Application number: 15/143,694
- Filed: 2016-05-02
- Published: 2016-08-25
- Earliest claimed: 2013-05-02
- Assignees: Mor Research Applications Ltd.
- Applicants: Mor Research Applications Ltd.
- Inventors: Moshe YESHURUN
- Web page: https://patentgrep.com/patent/US20160243055A1

## CPC

- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides methods for preventing, ameliorating and treating the acute and chronic forms of graft-versus-host disease (GVHD) by using Cannabidiol compositions.

## Claims

### Claim 1

A method for treating a subject afflicted with acute graft versus host disease (GVHD) or chronic GVHD comprising administering to said subject a therapeutically effective amount of a composition comprising a cannabidiol (CBD) or a functional derivative thereof, thereby treating a subject afflicted with acute graft versus host disease (GVHD) or chronic GVHD.

### Claim 2 (depends on 1)

The method of claim 1, wherein the acute GVHD is Grade III acute GVHD.

### Claim 3 (depends on 1)

The method of claim 1, wherein the acute GVHD is Grade IV acute GVHD.

### Claim 4 (depends on 1)

The method of claim 1, wherein the acute GVHD, the chronic GVHD, or both is/are refractory to a steroid treatment.

### Claim 5 (depends on 1)

The method of claim 1, wherein the chronic GVHD is severe chronic GVHD.

### Claim 6 (depends on 1)

The method of claim 1, wherein the chronic GVHD is classic or overlap chronic GVHD.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition is a systemic composition.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition is an oral composition or a topical composition.

### Claim 9 (depends on 1)

The method of claim 1, further comprising administering to the subject at least one additional GVHD therapeutic agent.

### Claim 10 (depends on 1)

The method of claim 1, wherein the CBD, or the functional derivative thereof, is administered daily in doses of between 5 mg to 600 mg.

### Claim 11 (depends on 1)

The method of claim 1, wherein the CBD, or the functional derivative thereof, is administered to the subject prior to or following diagnosis of acute or chronic GVHD in the subject.

### Claim 12 (depends on 1)

The method of claim 1, further comprising administering a steroid to said subject.

### Claim 13

A method for treating a subject afflicted with a condition associated with acute graft versus host disease (GVHD) or chronic GVHD, comprising administering to said subject a therapeutically effective amount of a composition comprising a cannabidiol (CBD) or a functional derivative thereof, thereby treating a subject afflicted with a condition associated with acute graft versus host disease (GVHD).

### Claim 14 (depends on 13)

The method of claim 13, wherein the condition is selected from the group consisting of: maculopapular rash, generalized erythroderma and bullous formation, hyperbilirubinemia, diarrhea, nausea, and scleroderma.

### Claim 15 (depends on 14)

The method of claim 14, wherein said treating said subject afflicted with hyperbilirubinemia is reducing bilirubin blood level by at least 20%.

### Claim 16 (depends on 13)

The method of claim 13, further comprising administering a steroid to said subject.

### Claim 17 (depends on 13)

The method of claim 13, wherein the condition appears within 100 days following hematopoietic stem cell transplant or donor lymphocyte infusion or after 100 days (late acute onset GVHD).

### Claim 18

A method for enhancing the therapeutic effect of a steroid in a subject in need of a steroid therapy, comprising administering to said subject said steroid and a cannabidiol (CBD) or a functional derivative thereof, thereby enhancing the therapeutic effect of a steroid in a subject in need of a steroid therapy.

### Claim 19 (depends on 18)

The method of claim 18, wherein said subject in need of a steroid therapy is afflicted with graft versus host disease (GVHD).

### Claim 20 (depends on 19)

The method of claim 19, wherein said GVHD is chronic GVHD or acute GVHD.

### Claim 21 (depends on 18)

The method of claim 18, wherein said enhancing the therapeutic effect of said steroid in said subject comprises reducing a side effect associated with said steroid.

### Claim 22 (depends on 18)

The method of claim 18, wherein said enhancing the therapeutic effect of a steroid is rendering a refractory steroid dose a therapeutic effective dose.

### Claim 23 (depends on 18)

The method of claim 18, wherein said enhancing the therapeutic effect of said steroid is reducing the effective dose of said steroid.
